Jump To Section
Featured Stories
J.P. Morgan, Without The Parties, Reveals An Industry Ready To Get Down To Business
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
J.P. Morgan Day 4: Setting Goals For The Year Ahead
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Viatris debuts; Chi-Med charts its own path; Novo takes another go at obesity; Sangamo moves forward with CAR-Treg; Intercept readies for resubmission; and ImmunoGen is relying on a safety advantage for its ADC.
Novavax Could Be The Next Biotech Winner In COVID-19 Vaccines
After years of setbacks, Novavax is on the cusp of success with its COVID-19 vaccine - but a rapid scale up of manufacturing and commercial operations will be a huge challenge.
Coronavirus Spotlight
After UK OK, Argentina Backs AstraZeneca/Oxford COVID-19 Vaccine
While the US and EU regulators seem less than keen on the data package offered to date on COVID-19 Vaccine AstraZeneca, Latin American countries are moving quickly to follow the UK in backing the cost-effective option.
Rolling Coverage Of The Coronavirus Outbreak And The Biopharma Industry's Response Is Here.
Latest News
Recent Tweets from Scrip
Infographics
The Race To Develop A COVID-19 Vaccine: mRNA Pioneers Lead The Way
Our updated graphic tracker of key developments from the leading vaccine candidates.
Infographic: Cancer Deal-Making In 2020
Despite the COVID-19 pandemic, 2020 has seen a hectic pace of cancer deal-making, including the two largest biopharma M&A deals of the year and 23 with upfront value of at least $100m.
The Top 10 Best-Selling Drugs of 2019
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Commercial Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
With US Respiratory Pipeline Unlocked, Cipla Wants Lung Leadership
Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.
Genmab/AbbVie’s Epcoritamab Advances As Deal Bears Fruit
The Danish company pockets $40m as the lead asset in the potential multi-billion dollar deal with AbbVie for bi-specific antibodies progresses into Phase III, and while it looks to build up its commercial infrastructure.
J.P. Morgan Day 3: Preparing For The Future, Whatever That Holds
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Teva promises growth is coming; Relay joins Roche in the KRAS race; UCB embraces the digital age; Agios and Ionis prepare for commercial battles.
Arena Updates Etrasimod Timelines, Introduces New Drug Candidate
CEO Amit Munshi told the J.P. Morgan meeting the company will double the size of its clinical-stage cardiovascular disease pipeline with the addition of temanogrel.
US COVID-19 Vaccination Rollout On Track After Early Bumps, J.P. Morgan Panelists Say
US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.
Deal Watch: Sanofi Teams Up With Biond On Novel Checkpoint Inhibitor
Days after buying Kymab, Sanofi partners with Israel’s Biond on IO candidate targeting ILT2. Gilead again tackles functional cure of hepatitis B in alliance with Vir.
Policy & Regulation Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Catchup Capsule: Key APAC Insights You Need To Read
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.
J.P. Morgan Day 2: Pharma Offers (Some) Views On Drug Pricing Reform
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Novartis explains its PD-1 deal; Biogen partners with Apple; Sanofi and Merck discuss business development priorities; and why AbbVie is confident it can grow without relying on deals.
Coronavirus Update: Moderna Vaccine Gets UK Go-Ahead As EU Approval of Oxford/AZ Vaccine Due In Weeks
Moderna’s mRNA COVID-19 vaccine has received an approval from the UK’s MHRA, while AstraZeneca is expected to apply for the EU approval of its COVID-19 vaccine next week.
Research & Development Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
One Year On: WHO Probe In Wuhan, Mixed Vaccine Results For Sinovac
One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.
Genmab/AbbVie’s Epcoritamab Advances As Deal Bears Fruit
The Danish company pockets $40m as the lead asset in the potential multi-billion dollar deal with AbbVie for bi-specific antibodies progresses into Phase III, and while it looks to build up its commercial infrastructure.
J.P. Morgan Day 3: Preparing For The Future, Whatever That Holds
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Teva promises growth is coming; Relay joins Roche in the KRAS race; UCB embraces the digital age; Agios and Ionis prepare for commercial battles.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.